Therapeutic immunization against mycobacterium tuberculosis is an effective adjunct to antibiotic treatment

Journal of Infectious Diseases

Volumn 207, Issue 8, 2013, Pages 1242-1252

  Coler, Rhea N ^a   Bertholet, Sylvie ^a   Pine, Samuel O ^a   Orr, Mark T ^a   Reese, Valerie ^a   Windish, Hillarie Plessner ^a   Davis, Charles ^a   Kahn, Maria ^a   Baldwin, Susan L ^a   Reed, Steven G ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; IMMUNOLOGICAL ADJUVANT; ISONIAZID; RIFAMPICIN; TUBERCULOSIS ID93 VACCINE; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NANOEMULSION; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TUBERCULOSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CHEMOTHERAPY, ADJUVANT; DISEASE MODELS, ANIMAL; FEMALE; ISONIAZID; LUNG; MACACA FASCICULARIS; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; RECURRENCE; RIFAMPIN; SURVIVAL ANALYSIS; TIME FACTORS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VACCINATION;

EID: 84875615118     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis425     Document Type: Article

References (46)

1. DyeC. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 2009; 7:81-7.
2. DolinPJ, RaviglioneMC, KochiA. Global tuberculosis incidence and mortality during 1900-2000. Bull.World Health Organ 1994; 72:213-20.
3. Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. Jama 2005; 293:2767-75.
4. Ginsberg AM, Spigelman M. Challenges in tuberculosis drug research and development. Nat Med 2007; 13:290-4.
5. Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology 2010; 15:603-22.
6. Salomon JA, Lloyd-Smith JO, Getz WM, et al. Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Med 2006; 3:e273.
7. Gill WP, Harik NS, Whiddon MR, Liao RP, Mittler JE, Sherman DR. A replication clock for Mycobacterium tuberculosis. Nat Med 2009; 15:211-4.
8. Roy E, Lowrie DB, Jolles SR. Current strategies in TB immunotherapy. Curr Mol Med 2007; 7:373-86.
9. Wejse C, Gustafson P, Nielsen J, et al. TBscore: signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. Scand J Infect Dis 2008; 40:111-20.
10. Andersen P. Tuberculosis vaccines-an update. Nat Rev Microbiol 2007; 5:484-7.
11. Nascimento E, Fernandes DF, Vieira EP, et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 + MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 2010; 28:6581-7.
12. Baldwin SL, Bertholet S, Kahn M, et al. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 2009; 27:3063-71.
13. Bertholet S, Ireton GC, Kahn M, et al. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol 2008; 181:7948-57.
14. Bertholet S, Ireton GC, Ordway DJ, et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2010; 2:53ra74.
15. Dietrich J, Aagaard C, Leah R, et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 2005; 174:6332-9.
16. Kaufmann SH, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet 2010; 375:2110-9.
17. Reed SG, Coler RN, Dalemans W, et al. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci USA 2009; 106:2301-6.
18. Skeiky YA, Ovendale PJ, Jen S, et al. T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J Immunol 2000; 165:7140-9.
19. Wang B, Henao-Tamayo M, Harton M, et al. A toll-like receptor-2 directed fusion protein vaccine against tuberculosis. Clin Vaccine Immunol 2007.
20. Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 2001; 69:2773-8.
21. Lowrie DB, Tascon RE, Bonato VL, et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999; 400:269-71.
22. Cardona PJ, Amat I, Gordillo S, et al. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine 2005; 23:1393-8.
23. Dietrich J, Weldingh K, Andersen P. Prospects for a novel vaccine against tuberculosis. Vet Microbiol 2006; 112:163-9.
24. Anderson RC, Fox CB, Dutill TS, et al. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces 2010; 75:123-32.
25. Coler RN, Bertholet S, Moutaftsi M, et al. Development of glucopyranosyl lipid A, a synthetic TLR4 agonist, as a vaccine adjuvant. PloS One 2011; 6:e16333.
26. Pantel A, Cheong C, Dandamudi D, et al. A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigento elicit Th1 T-cell immunity in vivo. Eur J Immunol 2011.
27. Bertholet S, Ireton GC, Kahn M, et al. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. Journal of immunology 2008; 181:7948-57.
28. Musa SA, Kim Y, Hashim R, Wang GZ, Dimmer C, Smith DW. Response of inbred mice to aerosol challenge with Mycobacterium tuberculosis. Infection and Immunity 1987; 55:1862-6.
29. Turner OC, Keefe RG, Sugawara I, Yamada H, Orme IM. SWR mice are highly susceptible to pulmonary infection with Mycobacterium tuberculosis. Infection and Immunity 2003; 71:5266-72.
30. Andersen PE. [Endovascular interventional treatment of hemoptysis]. Ugeskr Laeger 2005; 167:3160-3.
31. Ravn P, Brock I, Andersen P, Weldingh K. [A possible successor of the Mantoux test after 97 years]. Ugeskr Laeger 2005; 167:2905-6.
32. Walsh GP, Tan EV, dela Cruz EC, et al. The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat Med 1996; 2:430-6.
33. Langermans JA, Andersen P, van Soolingen D, et al. Divergent effect of bacillus Calmette-Guerin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research. Proc Natl Acad Sci USA 2001; 98:11497-502.
34. Langermans JA, Doherty TM, Vervenne RA, et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 2005; 23:2740-50.
35. Bachmanov AA, Reed DR, Beauchamp GK, Tordoff MG. Food intake, water intake, and drinking spout side preference of 28 mouse strains. Behav Genet 2002; 32:435-43.
36. Russell DG, Barry CE 3rd, Flynn JL. Tuberculosis: what we don't know can, and does, hurt us. Science 2010; 328:852-6.
37. Nikonenko BV, Einck L, Nacy CA. Anti-tuberculosis drug therapy in mice of different inbred strains. Infect Genet Evol 2010; 10:1151-4.
38. Turner OC, Sugawara , Yamada H, Cummings B, Orme IM Crystalloid inclusions in the cytoplasm of alveolar macrophages of the SwR/J mouse. A possible cause of susceptibility to mycobacterium tuberculosis? Journal of Submicroscopic Cytology and Pathology 2001; 33:217-9.
39. Wilkinson KA, Wilkinson RJ. Polyfunctional T cells in human tuberculosis. Eur J Immunol 2010; 40:2139-42.
40. Darrah PA, Patel DT, De Luca PM, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13:843-50.
41. Aagaard C, Hoang T, Dietrich J, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011; 17:189-94.
42. Mak A, Thomas A, Del Granado M, Zaleskis R, Mouzafarova N, Menzies D. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med 2008; 178:306-12.
43. Baldwin SL, Shaverdian N, Goto Y, et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009; 27:5956-63.
44. Bertholet S, Goto Y, Carter L, et al. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 2009; 27: 7036-45.
45. Wiley SR, Raman VS, Desbien A, et al. Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci Transl Med 2011; 3:93ra69.
46. Demissie A, Wassie L, Abebe M, et al. The 6-kilodalton early secreted antigenic target-responsive, asymptomatic contacts of tuberculosis patients express elevated levels of interleukin-4 and reduced levels of gamma interferon. Infect Immun 2006; 74:2817-22.